SCHEMBL6470632

SCHEMBL6470632

CC(C)NC(=O)c1cccc(-c2ccc(-n3cc(NC(N)=O)c(C(N)=O)n3)cc2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITK Q08881 1/20 0.48
IRAK4 Q9NWZ3 4/20 0.44
ERN1 O75460 3/20 0.43
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 3/20 0.43
MAPT P10636 2/20 0.43
NPC1 O15118 1/20 0.43
TP53 P04637 1/20 0.43
ALOX15 P16050 1/20 0.43
MAPK1 P28482 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HSD17B10 Q99714 1/20 0.43
PRKD1 Q15139 1/20 0.42
KCNH2 Q12809 1/20 0.42
ROCK2 O75116 2/20 0.41
CYP3A4 P08684 1/20 0.41
CYP3A5 P20815 1/20 0.41
LMNA P02545 2/20 0.41
XDH P47989 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6506090 0.86 IRAK4 (0.44) ITKIRAK4KDM4EALDH1A1MAPT
SCHEMBL6472225 0.86 KMO (0.46) ITKIRAK4KDM4EALDH1A1MAPT
SCHEMBL6499042 0.84 KDM4E (0.49) ITKIRAK4KDM4EALDH1A1MAPT
SCHEMBL6500421 0.83 NPC1 (0.47) ITKKDM4EALDH1A1MAPTNPC1
SCHEMBL6508388 0.82 ITK (0.47) ITKIRAK4KDM4EALDH1A1MAPT
SCHEMBL6505547 0.82 IRAK4 (0.53) ITKIRAK4KDM4EALDH1A1MAPT
SCHEMBL6469989 0.82 IRAK4 (0.56) ITKIRAK4KDM4EALDH1A1MAPT
SCHEMBL6497388 0.82 KDM4E (0.53) ITKIRAK4KDM4EALDH1A1MAPT
SCHEMBL6498765 0.81 MAPT (0.46) ITKIRAK4KDM4EALDH1A1MAPT
SCHEMBL6470300 0.81 ITK (0.52) ITKIRAK4KDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050197338-A1 Substituted pyrazole urea compounds for the treatment of inflammation PHARMACIA AND UPJOHN COMPANY LLC 2005-09-08 US disclosed
WO-2005037797-A1 SUBSTITUTED PYRAZOLE UREA COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197338-A1 Substituted pyrazole urea compounds for the treatment of inflammation IL4, ARG2, CASP4 ITK 4236/4885IRAK4 27/4885ERN1 1244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.